AtaiBeckley Inc. 8-K

What Happened AtaiBeckley Inc. announced on Feb. 19, 2026 (8-K filed) that Michael Faerm will become the Company’s Chief Financial Officer and principal financial officer effective when he commences employment with ATAI Life Sciences US, Inc., expected on March 9, 2026. Mr. Faerm succeeds Anne Johnson, who will become Chief Accounting Officer and remain the principal accounting officer. The company furnished a press release about the executive transitions.

Key Details

• Appointment/effective dates: Employment agreement dated Feb. 18, 2026; expected start (Appointment Date) March 9, 2026. Press release issued Feb. 19, 2026.
• Compensation: initial base salary $525,000; target annual discretionary bonus = 40% of base; one‑time sign‑on cash bonus $85,000 (payable only if employed one year and subject to repayment in certain circumstances).
• Equity and vesting: stock option to purchase 1,275,000 shares (exercise price = fair market value at grant) on a standard four‑year vesting schedule; 285,000 restricted stock units vesting in equal annual installments over four years.
• Severance/change‑in‑control: if terminated without “cause” or for “good reason” (with release and covenant compliance) he is entitled to 0.75× base salary paid over nine months, prior-year earned bonus, and up to nine months COBRA; if termination occurs on or within 12 months after a change in control, he would instead receive a lump-sum equal to base salary plus target bonus, prior-year bonus, up to 12 months COBRA, and accelerated time-based equity vesting (and possible extension of option exercise period up to 12 months).

Why It Matters This 8‑K reports a leadership change at the finance function: a new CFO with recent biopharma finance and interim CFO experience, and material compensation and equity grants that could affect dilution and executive expense. Key items investors may watch are the timing of Mr. Faerm’s start date, how his hiring and equity grants affect share count over time, and any future disclosures about financial strategy or guidance that accompany this management change.